avadel pharmaceuticals plc shares gave back some of fridays big gains dropping 12 to 220 the stock more than doubled on friday in turn bouncing back from the 52week low of 105 hit on thursday the company said in a filing on thursday that it received a proposed final label and medication guide for lead drug candidate ft218 from the us food  drug administration the stock moved higher friday after oppenheimer analyst francois brisebois said thursdays move lower was an overreaction and the proposed final label and medication guide for ft218 is a positive as it gives confidence in the products approvability in their note friday oppenheimer reiterated its outperform rating but decreased its price target to 13 from 16 a share on tuesday analysts at needham dropped their price target to 6 from 14 a share while maintaining a buy rating